Please login to the form below

Not currently logged in
Email:
Password:

ADC

This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.

ASH18: CAR-T and drugs give new options for multiple myeloma

ASH18: CAR-T and drugs give new options for multiple myeloma

There are also updates expected on  GlaxoSmithKline’s anti-BCMA antibody-drug conjugate (ADC) GSK2857916 and Pfizer’s bispecific antibody PF-06863135.

Latest news

More from news
Approximately 2 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... As an ADC IMMU-132 contains SN-38,

  • Deal Watch January 2017 Deal Watch January 2017

    465. Abzena. Not disclosed. Licence. ThioBridge ADC linker technology. 300. Domain Therapeutics.

  • Deal Watch February 2016 Deal Watch February 2016

    Mersana could receive an additional $750m in milestones if the XMT-1522 and ADC programmes are successful, plus sales royalties. ... acquisition - company. 895. Mersana Therapeutics/ Takeda. XMT-1522, Fleximer-based ADC therapy targeting HER2-expressing

  • Deal Watch January 2016 Deal Watch January 2016

    Abzena/(Partner nd). Licence . Novel site specific ThioBridge antibody drug conjugate (ADC) linker technology.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Late to join the immuno-oncology race, ADC 1013 is a CD40 targeting antibody in phase I clinical studies; J&J assumes development responsibilities when the phase I studies are completed. ... Licence. 727. Alligator Bioscience. J&J. ADC 1013 in solid

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    conjugates (ADCs) for cancer. .

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics